116705-41-0

Basic information

• Product Name: (E)-6-(2-(dimethylamino)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione
• Synonyms: (E)-6-(2-(dimethylamino)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione
• CAS NO: 116705-41-0
• Molecular Weight: 226.192
• Mol File: 116705-41-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (E)-6-(2-(dimethylamino)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-6-(2-(dimethylamino)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione(116705-41-0)
• EPA Substance Registry System: (E)-6-(2-(dimethylamino)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione(116705-41-0)

Safety Data

• Hazardous Substances Data: 116705-41-0(Hazardous Substances Data)

Usage

General Description

(E)-6-(2-(dimethylamino)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione is a chemical compound with the molecular formula C9H8N4O4. It is a nitro-substituted pyrimidine derivative with a vinyl group containing a dimethylamino substituent. (E)-6-(2-(dimethylamino)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione is primarily used as an intermediate or starting material in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and functional groups make it a valuable building block for the production of biologically active molecules and materials. The presence of the nitro and vinyl groups also provides opportunities for further chemical modifications and derivatizations to tailor its properties for specific applications in medicinal and synthetic chemistry.

Upstream product

• 626-48-2 6-Methyluracil 
• 16632-21-6 5-nitro-6-methyluracil 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 16632-21-6 5-nitro-6-methyluracil 
• 1377432-93-3 tert-butyl ((3R)-1-(3-(2-cyanobenzyl)-4-oxo-7-(thiophen-3-yl)-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)piperidin-3-yl)carbamate 
• 1377432-74-0 2-((2-((R)-3-aminopiperidin-1-yl)-7-bromo-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-3-yl)methyl)benzonitrile 
• 1377432-75-1 2-((2-((R)-3-aminopiperidin-1-yl)-4-oxo-7-(pyridin-3-yl)-4H-pyrrolo[3,2-d]pyrimidin-3(5H)-yl)methyl)benzonitrile 
• 1377432-76-2 2-((2-((R)-3-aminopiperidin-1-yl)-4-oxo-7-(pyridin-4-yl)-4H-pyrrolo[3,2-d]pyrimidin-3(5H)-yl)methyl)benzonitrile 
• 1377432-77-3 2-((2-((R)-3-aminopiperidin-1-yl)-4-oxo-7-(thiophen-3-yl)-4H-pyrrolo[3,2-d]pyrimidin-3(5H)-yl)methyl)benzonitrile 
• 90993-29-6 2-chloro-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 
• 129872-83-9 5-benzyl-2,4-dichloro-5H-pyrrolo<3,2-d>pyrimidine 
• 928841-01-4 5-(benzyloxymethyl)-2,4-dichloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine 
• 1402148-73-5 N-tert-butyloxycarbonyl-2,4-dichloropyrrolo[3,2-d]pyrimidine 
• 65996-50-1 2,4-dihydroxy-5H-pyrrolo[3,2-d]pyrimidine 
• 65996-50-1 2,4-Dioxo-1,2,3,4-tetrahydropyrrolo<3,2-d>pyrimidine 
• 114685-01-7 2,4-Bis<(β-cyclohexen-1'-yl)ethylamino>pyrrolo<3,2-d>pyrimidine 
• 114685-02-8 N²,N⁴-Bis-(4-methoxy-phenyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine 

Relevant articles and documents

Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization

A novel dipeptidyl peptidase IV inhibitor hit (5, IC50 = 0.86 μM) was structurally derived from our recently disclosed preclinical candidate 4 by replacing the cyanobenzyl with a butynyl based on pharmacophore hybridization. A hit-to-lead optimization effort was then initiated to improve its potency. Most N-substituted analogs exhibited good in vitro activity, and compound 18o (IC50 = 1.55 nM) was identified to be a potent dipeptidyl peptidase IV inhibitor with a significantly improved pharmacokinetic properties (bioavailablity: 41% vs 82.9%; T1/2: 2 h vs 4.9 h).

Pyrrolopyrimidine ketone compound and preparation method and application thereof

The invention relates to a pyrrolopyrimidine ketone compound and a preparation method and application thereof, and belongs to the technical field of medicine. The pyrrolopyrimidine ketone compound having a structural feature of formula I, or a pharmaceutically acceptable salt thereof has a very good inhibition effect on DPP-IV, and almost no effect on activity of DPP-VIII and DPP-IX, can effectively control the blood glucose concentration of diabetic rats, and is safe and low in toxicity through the verification of pharmacological and toxicological tests. After being prepared into a medicine, the compound provided by the invention not only has an obvious efficacy but also has very small side effects, thus greatly improving the administration convenience and patient use compliance, therefore, the compound has obvious advantages compared with the same kind of medicine. The formula is shown in the specification.

SYNTHESIS AND BIOLOGICAL ACTIVITY OF AMINOPYRROLOPYRIMIDINES

-